These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24270241)

  • 21. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
    Junn E; Ronchetti RD; Quezado MM; Kim SY; Mouradian MM
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2047-52. PubMed ID: 12576551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
    Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
    Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.
    Xu Y; Zhang Y; Quan Z; Wong W; Guo J; Zhang R; Yang Q; Dai R; McGeer PL; Qing H
    Neurochem Res; 2016 Oct; 41(10):2788-2796. PubMed ID: 27364962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity.
    Hmila I; Vaikath NN; Majbour NK; Erskine D; Sudhakaran IP; Gupta V; Ghanem SS; Islam Z; Emara MM; Abdesselem HB; Kolatkar PR; Achappa DK; Vinardell T; El-Agnaf OMA
    FEBS J; 2022 Aug; 289(15):4657-4673. PubMed ID: 35090199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective Role of Quercetin against Alpha-Synuclein-Associated Hallmarks in Parkinson's Disease.
    Das SS; Jha NK; Jha SK; Verma PRP; Ashraf GM; Singh SK
    Curr Neuropharmacol; 2023; 21(7):1464-1466. PubMed ID: 36545726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
    Wang Z; Gao G; Duan C; Yang H
    Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
    Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG
    Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.
    Batelli S; Albani D; Rametta R; Polito L; Prato F; Pesaresi M; Negro A; Forloni G
    PLoS One; 2008 Apr; 3(4):e1884. PubMed ID: 18382667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.
    Peng C; Gathagan RJ; Covell DJ; Medellin C; Stieber A; Robinson JL; Zhang B; Pitkin RM; Olufemi MF; Luk KC; Trojanowski JQ; Lee VM
    Nature; 2018 May; 557(7706):558-563. PubMed ID: 29743672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease.
    Bhattacharjee P; Öhrfelt A; Lashley T; Blennow K; Brinkmalm A; Zetterberg H
    J Proteome Res; 2019 May; 18(5):2109-2120. PubMed ID: 30943367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity.
    Francelle L; Outeiro TF; Rappold GA
    Sci Rep; 2020 Apr; 10(1):6064. PubMed ID: 32269243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
    Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
    Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
    J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.